Immunovant, Inc.
IMVT
$13.86
-$1.36-8.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.98% | 22.22% | 17.90% | 19.29% | 7.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.79% | 43.24% | 27.64% | 29.74% | 32.60% |
| Operating Income | -59.79% | -43.24% | -27.64% | -29.74% | -32.60% |
| Income Before Tax | -56.56% | -26.35% | -11.03% | -22.67% | -23.47% |
| Income Tax Expenses | 182.16% | 273.29% | 285.03% | 6,200.00% | -166.40% |
| Earnings from Continuing Operations | -57.20% | -26.54% | -11.46% | -22.93% | -22.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.20% | -26.54% | -11.46% | -22.93% | -22.52% |
| EBIT | -59.79% | -43.24% | -27.64% | -29.74% | -32.60% |
| EBITDA | -59.80% | -43.24% | -27.64% | -29.75% | -32.61% |
| EPS Basic | -43.10% | -12.80% | 0.52% | -10.55% | -10.48% |
| Normalized Basic EPS | -50.38% | -23.54% | -8.88% | -9.72% | -10.73% |
| EPS Diluted | -43.10% | -12.80% | 0.52% | -10.55% | -10.48% |
| Normalized Diluted EPS | -50.38% | -23.54% | -8.88% | -9.72% | -10.73% |
| Average Basic Shares Outstanding | 9.15% | 12.04% | 12.24% | 12.25% | 12.09% |
| Average Diluted Shares Outstanding | 9.15% | 12.04% | 12.24% | 12.25% | 12.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |